The Capital Markets Day will provide an opportunity for investors, analysts, and media to get insights into Cereno's clinical and preclinical development portfolio and operations as well as its future growth strategy. The program includes presentations by the Cereno Executive Management Team as well as external speakers

The interest for the Capital Markets Day has been high and the event at Posthuset in Stockholm is fully booked. For those not attending on site, there is an opportunity to participate virtually.

Date: October 17
Time: 13:30-16:30 CET
Venue: Online
Register here: https://lnkd.in/djQdTmsY

Aside from the live streaming, a video of the Capital Markets Day presentations will be shared subsequently on Cereno's website (http://www.cerenoscientific.com/), Youtube (https://www.youtube.com/@cerenoscientific)and LinkedIn (https://www.linkedin.com/company/cereno-scientific-ab).

AGENDA - Cereno Scientific's Capital
Markets Day, Thursday Oct 17th 13:30
-16:30, 2024
Topic Speaker
Introduction to Cereno Scientific and Sten R. Sörensen
current strategic priorities 
CEO, Cereno Scientific
Understanding PAH, a debilitating rare Dr. Raymond Benza
disease
Network Director of Pulmonary
Hypertension at Mount Sinai Icahn
School of Medicine, New York City.
Cereno Scientific's CS1 in PAH Dr. Rahul Agrawal, CMO and Head of
R&D, Cereno
Cereno Scientific's CS1 - Phase IIa trial Dr. Rahul Agrawal, CMO and Head of
results R&D, Cereno

Nicholas Oakes, Head of
Preclinical Development, Cereno
Scientific
Investigator and patient perspective of Dr. Jason Guichard, Cardiologist
CS1-003 trial at Prisma Health-Upstate,
Assistant Professor of Medicine,
University of South Carolina
School of Medicine Greenville and
investigator in the Phase IIa
trial of CS1 in PAH
Next steps for CS1 Dr. Rahul Agrawal, CMO and Head of
R&D, Cereno Scientific
Introduction to Fluidda and the innovative Jan De Backer, CEO, Fluidda
Functional Respiratory Imaging technology
Short break
CS014 - current status and future Dr. Björn Dahlöf, CSO, Cereno
perspectives Scientific
CS585 - current status and future Dr. Michael Holinstat
perspectives
Prof. at University of Michigan
Medical School; and Director
Translation Research, Cereno
Scientific
Cereno Scientific - future outlook Sten R. Sörensen

CEO, Cereno Scientific
Questions from Audience on site and online Moderated by Dr. Rahul Agrawal,
CMO
Concluding remarks Sten R. Sörensen

CEO, Cereno Scientific

For further information, please contact:

Henrik Westdahl, Director IR & Communications

Email:henrik.westdahl@cerenoscientific.com

Phone: +46 70-817 59 96

Sten R. Sörensen, CEO

Email:sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for rare and common cardiovascular diseases. The lead drug candidate, CS1, is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase IIa trial evaluating CS1's safety, tolerability, and exploratory efficacy in patients with the rare disease pulmonary arterial hypertension (PAH) demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. CS1 study data, together with preclinical information, is consistent with reversing pathological remodeling. A collaboration agreement with global healthcare company Abbott allowed Cereno to use their cutting-edge technology CardioMEMS HF System in the trial. Since January 2024, we are delighted that the FDA's Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno's pipeline comprises two additional programs in development through research collaborations with the University of Michigan. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator - regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without an increased risk of bleeding as documented in preclinical trials. The drug candidate has also demonstrated a favorable profile in preclinical models of other cardiovascular diseases, such as PAH, with reverse remodeling of pulmonary arterial vessels and effects on vascular fibrosis. On 28th of June, 2024, Cereno initiated a first-in-human Phase I trial of CS014. Preclinical candidate CS585 is an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding. CS585 was in-licensed from the University of Michigan in 2023. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. Based in Kendall Square, Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B).The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se.More information is on www.cerenoscientific.com.